Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Cancer Treatment Reviews|October 5, 2023
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatmentsFenneke Zwierenga, Bianca A M H van Veggel, Anke van den Berg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 15, 2010
Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRIAdrianus J de Langen, Vivian van den Boogaart, Mark Lubberink, et al.
JTO Clinical and Research Reports|December 1, 2021
Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLCLiesbeth M Hondelink, Merel Jebbink, Jan H von der Thüsen, et al.
JAMA Oncology|July 12, 2019
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical TrialWillemijn S M E Theelen, Heike M U Peulen, Ferry Lalezari, et al.
Cancer|October 31, 2023
A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancerBianca A M H van Veggel, Anthonie J van der Wekken, Marthe S Paats, et al.
Targeted Oncology|June 5, 2025
Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose OsimertinibFenneke Zwierenga, M Benthe Muntinghe-Wagenaar, Pim Rozendal, et al.
Cancer Chemotherapy and Pharmacology|November 6, 2025
Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicityRob Ter Heine, Bianca J C van den Bosch, Robin M van Geel, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARDZofia Piotrowska, Sarah B Goldberg, Jonathan W Goldman, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 26, 2023
A qualitative study on the healthcare experiences of adolescents and young adults (AYA) with an uncertain or poor cancer prognosisVivian W G Burgers, Milou J P Reuvers, Martin J B Taphoorn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2020
Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung CancerRosemarie de Haan, Michel M van den Heuvel, Judi van Diessen, et al.
Pageof 8